Enhanced potency of covalently modified granulocyte colony-stimulating factor

Casim Sarkar, Peggy Wang, Douglas Lauffenburger

Research output: Contribution to journalConference articlepeer-review


We have measured the degradation of GCSF and a PEGylated GCSF analog (SD/01) over time in vitro, and both fit a first-order depletion model. We found that SD/01 has a 5-fold longer half-life than GCSF at starting concentrations of 270 pM. However, an increase in the cellular response due to SD/01 was not noticeable until after the fifth day. These results suggest that GCSF and SD/01 may have different trafficking properties.

Original languageEnglish (US)
Pages (from-to)S-83
JournalAnnals of Biomedical Engineering
Issue numberSUPPL. 1
StatePublished - 2000
Event2000 Annual Fall Meeting of the Biomedical Engineering Society - Washington, WA, USA
Duration: Oct 12 2000Oct 14 2000


Dive into the research topics of 'Enhanced potency of covalently modified granulocyte colony-stimulating factor'. Together they form a unique fingerprint.

Cite this